Claudin 18.2 Detection with Optimized IHC Solutions

Claudin 18.2, a tight junction protein predominantly expressed in the gastric epithelium, has gained significant attention for its selective overexpression in various cancers, including gastric adenocarcinoma, pancreatic, and lung malignancies. Its restricted expression in normal tissues makes it an ideal therapeutic target, minimizing off-target effects. Importantly, heterogeneity in CLDN18.2 expression between primary and metastatic sites complicates therapeutic strategies, emphasizing the need for comprehensive diagnostic protocols using immunohistochemistry (IHC) and other molecular assays.

Recent studies have uncovered the role of CLDN18.2 in promoting tumor progression through interactions with cancer-associated fibroblasts (CAFs). These interactions drive cellular adhesion, migration, and invasion, highlighting CLDN18.2's role in the tumor microenvironment. Such insights have guided the development of innovative therapies, including antibody-drug conjugates and bispecific antibodies. Zolbetuximab, an anti-CLDN18.2 monoclonal antibody, has shown promise in clinical trials, paving the way for targeted treatment approaches.

The integration of CLDN18.2-targeted therapies into oncology holds potential to improve outcomes in cancers with overexpression of this protein.

We offer a comprehensive range of anti-Claudin 18.2 antibodies. These products include high-affinity monoclonal and polyclonal antibodies optimized for IHC.

Browse Now

Please note that the antibodies listed are just a small sample of the variety we offer. We have a wide range of antibodies available for different applications, and we are happy to provide more information upon request.

Browse Now

Contact us for more information